by Rhoda Wilson, Expose News:
In 2022, an outbreak of mpox (formerly known as monkeypox) garnered global attention, leading to a public health emergency declaration by the WHO.
In 2023, a new variant of the virus emerged, resulting in over 21,000 reported cases by August 2024. WHO declared the epidemic a public health emergency of international concern in August 2024.
The Project BioShield Act of 2004 aimed to defend against bioterrorism by accelerating the research and availability of medical countermeasures. This led to the development of Jynneos, the first approved monkeypox vaccine developed by Bavarian Nordic.
TRUTH LIVES on at https://sgtreport.tv/
A second smallpox vaccine, ACAM2000, was approved for use against mpox by the US Food and Drug Administration last month. This second vaccine is manufactured by the controversial Emergent BioSolutions.
Among ACAM2000 horrifying adverse effects is that the live vaccinia virus, which the vaccine contains, can be transmitted to persons who have close contact with the vaccinee causing the same horrific adverse effects, including death.
How could ACAM2000 have gotten approval in the first place? Former US Assistant Secretary of Health and Human Services (Preparedness and Response) Robert Kadlec and his connections might provide the answer.
Mpox, Project Bioshield: Everyone’s Dark Winter?
By Sonia Elijah as published by the Brownstone Institute
In 2022, mpox (formerly known as monkeypox) drew worldwide attention, when more than 20 countries reported infections to the World Health Organisation (“WHO”) by May of that year. It led to WHO Director-General, Tedros Adhanom Ghebreyesus, declaring the mpox outbreak involving clade IIb of the virus in the Democratic Republic of the Congo and its expansion to neighbouring countries, a global health emergency.
The monkeypox virus is part of the same family of viruses (orthopoxviruses) as smallpox but is less severe. In 1980, the World Health Assembly announced that smallpox had been eradicated and recommended that all countries cease vaccination. Although labs in two countries still officially store smallpox samples (US and Russia).
Mpox was first identified in Denmark, in 1958, when two outbreaks of a pox-like disease occurred in laboratory monkeys, which is how it got its name – although monkeys are not considered to be reservoirs for the virus. The source of the virus is said to be unknown.
In 1970, the first human case of mpox was recorded in the Democratic Republic of the Congo. This was during a time when smallpox was being eradicated. The disease is considered to be endemic to countries in central and west Africa. The outbreaks have been concentrated among men who have sex with men.
In late September 2023, the emergence of a new variant of the virus was detected in central Africa. As of August 2024, more than 21,000 cases have been reported, with over 600 fatalities, nearly all in the Democratic Republic of the Congo.
On 14 August 2024, WHO declared the epidemic a public health emergency of international concern (“PHEIC”).
A month after the WHO’s announcement, the small Danish biotechnology firm, Bavarian Nordic, became the first in the world to receive approval for a monkeypox vaccine, Jynneos (known internationally as Imvamune or Imvanex), initially developed for smallpox but was rarely used.
In the wake of the September 2001 anthrax attacks, President George W. Bush signed into law the Project BioShield Act of 2004 (“Project BioShield”) “as part of a broader strategy to defend America against the threat of weapons of mass destruction. The purpose of Project BioShield is to accelerate the research, development, purchase and availability of effective medical countermeasures against biological, chemical, radiological and nuclear (CBRN) threats.”
Project Bioshield was a ten-year program managed by the Biomedical Advanced Research and Development Authority (“BARDA”), part of the United States Department of Health and Human Services (“HHS”).
